stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.32
0.05
+0.95%
Follow RGC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | — | — | 0 | (1) | (1) | (8) | (6) | (4) | (4) | (12) | +62.5% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | 0 | — | 0 | (1) | (1) | (8) | (6) | (4) | (4) | (12) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | 0.00 | 0.00 | 0.00 | (0.02) | (0.01) | (0.01) | (0.01) | (0.02) | +53.4% | ||||||
| Cash flow | — | — | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.02) | +48.1% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.02) | +48.1% | ||||||
| Book value | — | — | 0.00 | (0.01) | (0.01) | 0.04 | 0.02 | 0.02 | 0.01 | 0.03 | n/m | ||||||
| Shares, m | — | — | 380 | 380 | 380 | 487 | 494 | 494 | 494 | 495 | +3.8% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | (1) | (1) | (5) | (5) | (4) | (3) | (8) | +53.1% | |||||
| Capex | — | — | — | 0 | — | (1) | 0 | 0 | 0 | — | +5.3% | ||||||
| Free cash flow | — | — | 0 | (1) | (1) | (6) | (5) | (4) | (3) | (8) | +53.1% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | (2) | (3) | (4) | 16 | 11 | 8 | 4 | 13 | n/m | |||||
| Net debt | — | — | 0 | 0 | 0 | (16) | (12) | (8) | (5) | (14) | +78.8% | ||||||
| Shareholders’ equity | — | — | (2) | (3) | (4) | 17 | 12 | 8 | 5 | 13 | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | (321.41) | (214.55) | (315.35) | (81.11) | (38.32) | (40.85) | (50.50) | (114.25) | +207.2 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (717.14) | (923.47) | (1,149.68) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 17.42 | 36.19 | 40.51 | (113.82) | (40.39) | (42.58) | (54.81) | (128.52) | (145.9) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | 8 | 13 | 13 | 12 | 12 | 10 | 10 | +3.8% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Regencell Bioscience Holdings Limited vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. | $3.5B | — (loss-making) | — (loss-making) | −100.61% (below 0%: shrinking) | n/m | −24.50% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RGC Regencell Bioscience Holdings Limited | $2.6B | — (loss-making) | — | — | — | +57.15% (above 0%: growing) | 0.00% | — | |
| HCM HUTCHMED (China) Limited Sponsored ADR | $2.5B | — (loss-making) | — | +510.07% (above 0%: growing) | +419.25% (above 0%: growing) | +113.21% (above 0%: growing) | 60.90% | 0.00% | Compare |
| XERS Xeris Biopharma Holdings, Inc. | $2.4B | — (loss-making) | — (loss-making) | +44.16% (above 0%: growing) | +1,478.95% (above 0%: growing) | +93.18% (above 0%: growing) | 88.41% | 15.78% | Compare |
| PRGO Perrigo Company plc | $2.2B | — (loss-making) | — (loss-making) | −5.24% (below 0%: shrinking) | n/m | +138.48% (above 0%: growing) | 32.45% | 2.34% | Compare |
| PBH Prestige Consumer Healthcare Inc. | $2.1B | 13.2× | 11.7× | +22.69% (above 0%: growing) | −38.07% (below 0%: shrinking) | −38.18% (below 0%: shrinking) | 51.30% | 24.00% | Compare |
| TRLV Trulieve Cannabis Corp. | $2.1B | — (loss-making) | — (loss-making) | −20.12% (below 0%: shrinking) | n/m | +24.49% (above 0%: growing) | 64.30% | 0.00% | Compare |
| BCRX BioCryst Pharmaceuticals, Inc. | $2.0B | — (loss-making) | — (loss-making) | +13.11% (above 0%: growing) | +147.17% (above 0%: growing) | −18.69% (below 0%: shrinking) | 99.13% | 29.58% | Compare |
| ALVO Alvotech | $1.8B | — (loss-making) | 111× | +2,310.95% (above 0%: growing) | −99.51% (below 0%: shrinking) | −496.58% (below 0%: shrinking) | 56.47% | 9.14% | Compare |
| Median of peers | $2.1B | — | — | +17.90% | +147.17% | +2.90% | 62.60% | 5.74% |